Systems pharmacology augments drug safety surveillance

Clinical Pharmacology and Therapeutics

Volumn 97, Issue 2, 2015, Pages 151-158

  Lorberbaum, T ^a   Nasir, M ^a   Keiser, M J ^b,c   Vilar, S ^a   Hripcsak, G ^a,d   Tatonetti, N P ^a,d  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Observational Health Data Sciences and Informatics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; ARTICLE; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; PREDICTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; BIOLOGICAL MODEL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENOMICS; HUMAN; PATIENT SAFETY; PHARMACOLOGY; SYSTEMS BIOLOGY;

ALGORITHMS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENOMICS; HUMANS; MODELS, BIOLOGICAL; PATIENT SAFETY; PHARMACOLOGY; PHARMACOVIGILANCE; SYSTEMS BIOLOGY;

EID: 84929148014     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.2     Document Type: Article

References (45)

1. Graham, D.J., Campen, D., Hui, R., Spence, M., Cheetham, C. & Levy G. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study. Lancet 365, 475-481 (2005).
2. Nissen, S.E., Nissen, S.E., Wolski, K. & Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471 (2007).
3. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711-715 (2004).
4. Berlin, J.A., Glasser, S.C. & Ellenberg, S.S. Adverse event detection in drug development: Recommendations and obligations beyond phase 3. Am. J. Public Health 98, 1366-1371 (2008).
5. Tatonetti, N.P., Ye, P.P., Daneshjou, R. & Altman, R.B. Data-driven prediction of drug effects and interactions. Sci. Trans. Med. 4, 125ra31-125ra31 (2012).
6. Harpaz, R., DuMouchel, W., Shah, N.H., Madigan, D., Ryan, P.B. & Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin. Pharmacol. Ther. 91, 1010-1021 (2012).
7. Ryan, P.B., Madigan, D., Stang, P.E., Overhage, J.M., Racoosin, J.A. & Hartzema G.H. Empirical assessment of methods for risk identification in healthcare data: Results from the experiments of the Observational Medical Outcomes Partnership. Stat. Med. 31, 4401-4415 (2012).
8. Bate, A. & Evans, S.J.W. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidem Drug Saf. 18, 427-436 (2009).
9. Stephenson, W.P. & Hauben, M. Data mining for signals in spontaneous reporting databases: Proceed with caution. Pharmacoepidem Drug Saf. 16, 359-365 (2007).
10. DuMouchel, W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am. Stat. 53, 177-190 (1999).
11. Szarfman, A., Machado, S.G. & O'Neill, R.T. Use of screening algorithms and computer systems to efficiently signal higher-thanexpected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf. 25, 381-392 (2002).
12. Simpson, S.E. A positive event dependence model for self-controlled case series with applications in postmarketing surveillance. BIOM 69, 128-136 (2012).
13. Hopkins, A.L. Network pharmacology: The next paradigm in drug discovery. Nat. Chem. Biol. 4, 682-690 (2008).
14. Jacunski, A. & Tatonetti, N.P. Connecting the dots: Applications of network medicine in pharmacology and disease. Clin. Pharmacol. Ther. 94, 659-669 (2013).
15. Berger, S.I. & Iyengar, R. Network analyses in systems pharmacology. Bioinformatics 25, 2466-2472 (2009).
16. Duran-Frigola, M. & Aloy, P. Analysis of chemical and biological features yields mechanistic insights into drug side effects. Chem. Biol. 20, 594-603 (2013).
17. Berger, S.I., Ma'ayan, A. & Iyengar, R. Systems pharmacology of arrhythmias. Sci. Signal. 3, ra30-ra30 (2010).
18. Gottlieb, A. & Altman, R.B. Integrating systems biology sources illuminates drug action. Clin. Pharmacol. Ther. 95, 663-669 (2014).
19. Cami, A., Arnold, A., Manzi S. & Reis, B. Predicting adverse drug events using pharmacological network models. Sci. Transl. Med. 3, 114ra127-114ra127 (2011).
20. Ryan, P.B., Madigan, D., Stang, P.E., Schuemie, M.J. & Hripcsak, G. Medication-wide association studies. CPT: Pharmacomet Syst. Pharmacol. 2, e76 (2013).
21. Franceschini, A., Szklarczyk, D., Frankild, S., Kuhn, M., Simonovic, M. & Roth A. STRING v9.1: Protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 41, D808-D815 (2012).
22. Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A.C. & Liu, Y., DrugBank 4.0: Shedding new light on drug metabolism. Nucleic Acids Res. 42, D1091-D1097 (2013).
23. Kr€otz, F., Schiele, T.M., Klauss, V. & Sohn H.-Y. Selective COX-2 inhibitors and risk of myocardial infarction. J. Vasc. Res. 42, 312-324 (2005).
24. Vikenes, K., Farstad, M. & Nordrehaug, J.E. Serotonin is associated with coronary artery disease and cardiac events. Circulation 100, 483-489 (1999).
25. Nabel, E.G., Nabel, E.G., Braunwald, E. & Braunwald, E. A tale of coronary artery disease and myocardial infarction. N. Engl. J. Med. 366, 54-63 (2012).
26. Nilsson, T., Longmore, J., Shaw, D., Pantev, E., Bard, J.A. & Branchek T. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur. J. Pharmacol. 372, 49-56 (1999).
27. Ito, T., Ikeda, U., Shimpo, M., Yamamoto, K. & Shimada, K. Serotonin increases interleukin-6 synthesis in human vascular smooth muscle cells. Circulation 102, 2522-2527 (2000).
28. Kolluri, S.K., Corr, M., James, S.Y., Bernasconi, M., Lu, D. & Liu W. The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Proc. Natl. Acad. Sci. USA 102, 2525-2530 (2005).
29. Libby, P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104, 365-372 (2001).
30. Giaginis, C., Klonaris, C., Katsargyris, A., Kouraklis, G., Spiliopoulou, C. & Theocharis, S. Correlation of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and retinoid X receptor-alpha (RXRalpha) expression with clinical risk factors in patients with advanced carotid atherosclerosis. Med. Sci. Monit. 17, CR381-91 (2011).
31. Hald, E.M., Lijfering, W.M., Mathiesen, E.B., Johnsen, S.H., Løchen, M.-L. & Njølstad I. Carotid atherosclerosis predicts future myocardial infarction but not venous thromboembolism: The Tromso Study. Arterioscler. Thromb. Vas. Biol. 34, 226-230 (2013).
32. Hansson, G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685-1695 (2005).
33. Marks, A.R. Calcium cycling proteins and heart failure: Mechanisms and therapeutics. J. Clin. Invest. 123, 46-52 (2013).
34. Langenbach, R., Morham, S.G., Tiano, H.F., Loftin, C.D., Ghanayem, B.I. & Chulada, P.C. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83, 483-492 (1995).
35. Sturgill, M.G. & Lambert, G.H. Xenobiotic-induced hepatotoxicity: Mechanisms of liver injury and methods of monitoring hepatic function. Clin. Chem. 43, 1512-1526 (1997).
36. Zhao, X.-M., Iskar, M., Zeller, G., Kuhn, M., Noort, V.V. & Bork P. Prediction of drug combinations by integrating molecular and pharmacological data. PLoS Comput. Biol. 7, e1002323 (2011).
37. Wang, Y.-Y., Xu, K.-J., Song, J. & Zhao X.-M. Exploring drug combinations in genetic interaction network. BMC Bioinform. 13, S7 (2012).
38. Cheng, F. & Zhao, Z. Machine learning-based prediction of drug-drug interactions by integrating drug phenotypic, therapeutic, chemical, and genomic properties. J. Am. Med Inform. Assoc. 21, e278-286 (2014).
39. Stelzer, G., Dalah, I., Stein, T.I., Satanower, Y., Rosen, N. & Nativ N. In-silico human genomics with GeneCards. Hum. Genom. 5, 709-717 (2011).
40. Knox, C., Law, V., Jewison, T., Liu, P., Ly, S. & Frolkis, A. DrugBank 3.0: A comprehensive resource for 'Omics' research on drugs. Nucleic Acids Res. 39, D1035-D1041 (2010).
41. Hagberg, A., Swart, P. & Chult, D. Exploring network structure, dynamics, and function using NetworkX. Proceedings of the 7th Python in Science Conference (SciPy 2008) (2008).
42. Pedregosa, F., Varoquaux, G., Gramfort, A., Michel, V., Thirion, B. & Grisel, O. Scikit-learn: Machine learning in Python. J. Mach. Learn Res. 12, 2825-2830 (2011).
43. Robin, X., Turck, N., Hainard, A., Tiberti, N., Lisacek, F. & Sanchez, JC. pROC: An open-source package for R and S1 to analyze and compare ROC curves. BMC Bioinform. 12, 77 (2011).
44. Huang, D.W., Sherman, B.T. & Lempicki, R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57 (2008).
45. Smoot, M.E., Ono, K., Ruscheinski, J., Wang, P.L. & Ideker, T. Cytoscape 2.8: New features for data integration and network visualization. Bioinformatics 27, 431-432 (2011).